Foghorn Therapeutics
Foghorn Therapeutics is a pioneering biotechnology company focused on developing a new class of medicines that treat serious diseases by correcting abnormal gene expression through targeting the chromatin regulatory system. Their proprietary Gene Traffic Control® platform enables them to identify and modulate genetic dependencies within this system, with a broad pipeline of product candidates in oncology and beyond. The company's mission is to transform the lives of people with a wide spectrum of diseases by leveraging their deep scientific insights into chromatin biology.
Industries
Nr. of Employees
medium (51-250)
Foghorn Therapeutics
500 Technology Square, Suite 700, Cambridge, MA 02139
Patents
Citrate salt, pharmaceutical compositions, and methods of making and using the same
US-11767330-B2
View Details
Citrate salt, pharmaceutical compositions, and methods of making and using the same
US-11767330-B2
View DetailsProducts
Clinical-stage selective SMARCA2 oral ATPase inhibitor (Phase 1)
A potent, orally available selective inhibitor of SMARCA2 ATPase activity developed as a precision therapy for cancers with SMARCA4 alterations; evaluated in a Phase 1 study for safety, tolerability and initial efficacy.
Clinical-stage selective SMARCA2 oral ATPase inhibitor (Phase 1)
A potent, orally available selective inhibitor of SMARCA2 ATPase activity developed as a precision therapy for cancers with SMARCA4 alterations; evaluated in a Phase 1 study for safety, tolerability and initial efficacy.
Services
Target identification using sequencing and computational tools, production of target components, and deployment of proprietary biochemical and cell-based assays to support discovery and optimization.
Execution of strategic alliances for co-development and co-commercialization of oncology programs and discovery-stage collaborations using the proprietary discovery platform.
Target identification using sequencing and computational tools, production of target components, and deployment of proprietary biochemical and cell-based assays to support discovery and optimization.
Execution of strategic alliances for co-development and co-commercialization of oncology programs and discovery-stage collaborations using the proprietary discovery platform.
Expertise Areas
- Chromatin biology and epigenetics
- Genomic target identification and validation
- Targeted protein degradation (induced-proximity modalities)
- Small-molecule drug discovery and lead optimization
Key Technologies
- Next-generation sequencing and computational genomics
- High-throughput screening
- Targeted protein degradation (PROTAC and induced-proximity)
- Allosteric small-molecule inhibitors (ATPase inhibition)
News & Updates
Foghorn’s Q1 earnings release provides financial updates and insights into the company's progress.
Foghorn’s Q1 earnings release provides financial updates and insights into the company's progress.